Napredna pretraga

Pregled bibliografske jedinice broj: 672823

A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma


Roy, A.C.; Park, S.R.; Cunningham, D.; Kang, Y.K.; Chao, Y.; Chen, L.T.; Rees, C.; Lim, H.Y.; Tabernero, J.; Ramos, F.J. et al.
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma // Annals of oncology, 24 (2013), 6; 1567-1573 doi:10.1093/annonc/mdt002 (međunarodna recenzija, članak, znanstveni)


Naslov
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma

Autori
Roy, A.C. ; Park, S.R. ; Cunningham, D. ; Kang, Y.K. ; Chao, Y. ; Chen, L.T. ; Rees, C. ; Lim, H.Y. ; Tabernero, J. ; Ramos, F.J. ; Kujundžić, Milan ; Cardic, M.B. ; Yeh, .C.G ; de Gramont, A.

Izvornik
Annals of oncology (0923-7534) 24 (2013), 6; 1567-1573

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Docetaxel; irinotecan; liposomal irinotecan; oesophago-gastric cancer; phase II; second line

Sažetak
PEP02 is a novel highly stable liposomal nanocarrier formulation of irinotecan. This randomized phase II study evaluated the efficacy and safety of single agent PEP02 compared with irinotecan or docetaxel in the second-line treatment of advanced oesophago-gastric (OG) cancer. Patients with locally advanced/metastatic disease who had failed one prior chemotherapy regimen were randomly assigned to PEP02 120 mg/m(2), irinotecan 300 mg/m(2) or docetaxel (Taxotere) 75 mg/m(2) every 3 weeks. The primary end point was objective response rate (ORR). Simon's two-stage design was used and the ORR of interest was 20% (α = 0.05, type II error β = 0.10, null hypothesis of ORR was 5%). Forty-four patients per arm received treatment, and 124 were assessable for response. The ORR statistical threshold for the first stage was reached in all arms. In the intent-to-treat (ITT) population, ORRs were 13.6% (6/44), 6.8% (3/44) and 15.9% (7/44) in the PEP02, irinotecan and docetaxel arms, respectively. The median progression-free survival (PFS) and overall survival were similar between the trial arms. Commonest grade 3-4 adverse event reported was diarrhoea in the PEP02 and irinotecan groups (27.3% versus 18.2%). The ORR associated with PEP02 was comparable with docetaxel and numerically greater than that of irinotecan. PEP02 warrants further evaluation in the advanced gastric cancer setting.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti



POVEZANOST RADA


Projekt / tema
108-0000000-3114 - HELICOBAKTER PYLORI INFEKCIJA - EVOLUCIJA BOLESTI I NOVI TERAPIJSKI POSTUPCI (Miroslava Katičić, )
198-0000000-1124 - Bolesti pankreato-bilijarnog sustava: etiologija, dijagnostika i terapija (Milan Kujundžić, )

Ustanove
Medicinski fakultet, Zagreb,
Klinička bolnica "Dubrava"

Autor s matičnim brojem:
Milan Kujundžić, (168490)

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Uključenost u ostale bibliografske baze podataka:


  • EMBASE (Excerpta Medica)
  • MEDLINE


Citati